Navigation path

Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information

Imatinib mesylate

EU orphan designation number: EU/3/01/021
Active ingredient: Imatinib mesylate
Indication: Treatment of chronic myeloid leukaemia
Sponsor: Novartis Europharm Limited
Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Glivec on 27/08/2001 with the number EU/1/01/198

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
22/02/2001 Orphan designation EMEA/OD/049/00 (2001)361 of 14/02/2001
12/11/2011 Removal of orphan designation from Community Register